Paper33178203
Localized Interleukin-12 for Cancer Immunotherapy.
Nguyen KG and 6 others. Front Immunol, 2020. Cited by 363 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Localized Interleukin-12 for Cancer Immunotherapy. Papers, record 33178203. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33178203
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Genetic Therapy | Major topic |
| Immunotherapy | Major topic |
| Interleukin-12 | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Drug Carriers | |
| Drug Compounding | |
| Gene Transfer Techniques | |
| Genetic Vectors | |
| Humans | |
| Treatment Outcome | |
| Tumor Microenvironment |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA172631 | NCI NIH HHS | United States | R01CA172631 | PubMed and NIH |
Source NIH RePORTER
References389
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30080893 | A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. | PLoS Pathog | 2018 | https://conductscience.org/library/papers/30080893 | PubMed |
| 2 | 20157604 | Tumor Therapy Applying Membrane-bound Form of Cytokines. | Immune Netw | 2009 | https://conductscience.org/library/papers/20157604 | PubMed |
| 3 | 12810649 | Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. | Cancer Res | 2003 | https://conductscience.org/library/papers/12810649 | PubMed |
| 4 | 25639194 | Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma. | Int J Cancer | 2015 | https://conductscience.org/library/papers/25639194 | PubMed |
| 5 | 16763609 | Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma. | Cancer Gene Ther | 2006 | https://conductscience.org/library/papers/16763609 | PubMed |
| 6 | 9574551 | In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. | J Immunol | 1998 | https://conductscience.org/library/papers/9574551 | PubMed |
| 7 | 23924790 | Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. | J Immunother | 2013 | https://conductscience.org/library/papers/23924790 | PubMed |
| 8 | 22781695 | Oncolytic virotherapy. | Nat Biotechnol | 2012 | https://conductscience.org/library/papers/22781695 | PubMed |
| 9 | 19051291 | Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. | Cancer | 2009 | https://conductscience.org/library/papers/19051291 | PubMed |
| 10 | 7636204 | Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. | J Immunol | 1995 | https://conductscience.org/library/papers/7636204 | PubMed |
| 11 | 17310381 | Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies. | Cancer Immunol Immunother | 2007 | https://conductscience.org/library/papers/17310381 | PubMed |
| 12 | 28679778 | Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28679778 | PubMed |
| 13 | 10999765 | Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. | Clin Cancer Res | 2000 | https://conductscience.org/library/papers/10999765 | PubMed |
| 14 | 22549945 | The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. | Cancer Res | 2012 | https://conductscience.org/library/papers/22549945 | PubMed |
| 15 | 31142602 | Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma. | J Immunol | 2019 | https://conductscience.org/library/papers/31142602 | PubMed |
| 16 | 29123084 | Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. | Nat Commun | 2017 | https://conductscience.org/library/papers/29123084 | PubMed |
| 17 | 21228885 | The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. | Gene Ther | 2011 | https://conductscience.org/library/papers/21228885 | PubMed |
| 18 | 10561265 | High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. | J Clin Oncol | 1999 | https://conductscience.org/library/papers/10561265 | PubMed |
| 19 | 20539064 | Using poly-N-acetyl glucosamine gel matrix to deliver IL-12 with anti-schistosomasis vaccination. | J Infect Dev Ctries | 2010 | https://conductscience.org/library/papers/20539064 | PubMed |
| 20 | 9607576 | Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. | Clin Cancer Res | 1998 | https://conductscience.org/library/papers/9607576 | PubMed |
Cited by266
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 363 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42942783 | Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42942783 | PubMed |
| 42850494 | Small-molecule NFAT signaling inhibitor with dual NFATc1/NFATc2 activity and limited calcineurin catalytic inhibition. | Arch Pharm Res | 2026 | https://conductscience.org/library/papers/42850494 | PubMed |
| 42840974 | In situ vaccination for the treatment of localized cancer and the prevention of metastatic disease. | Front Immunol | 2026 | https://conductscience.org/library/papers/42840974 | PubMed |
| 42799424 | Polymeric Materials in Cancer Immunotherapy: Advances, Challenges, and Future Directions. | Polym Sci Technol | 2026 | https://conductscience.org/library/papers/42799424 | PubMed |
| 42771161 | Smart drug delivery systems for immunotherapeutic agents: focus on biological/biogenic platform-based intelligent delivery in cancer immunotherapy. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/42771161 | PubMed |
| 42749873 | Intratumor delivery of a novel plasmid combination induces high levels of metastatic melanoma regression. | Gene Ther | 2026 | https://conductscience.org/library/papers/42749873 | PubMed |
| 42737611 | αHSA-proIL-12: A Tumor-Conditional IL-12 Prodrug with Reduced Systemic Toxicity and Potent Antitumor Activity. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737611 | PubMed |
| 42662452 | FLASH radiotherapy as an emerging paradigm in radioimmunotherapy: biological rationale, preclinical evidence, and translational roadmap. | Front Immunol | 2026 | https://conductscience.org/library/papers/42662452 | PubMed |
| 42653221 | Immunotherapy for Cancer: Current Advances and Future Directions. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42653221 | PubMed |
| 42611979 | Safety and Efficacy of Intratumoral MEDI1191, an IL12 mRNA Lipid Nanoparticle, plus Intravenous Durvalumab in Patients with Advanced Solid Tumors: A First-in-Human Study. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42611979 | PubMed |
| 42558941 | Dendritic cell-based immunotherapy modulates the systemic inflammatory profile in a 4T1 breast cancer model. | Explor Target Antitumor Ther | 2026 | https://conductscience.org/library/papers/42558941 | PubMed |
| 42536026 | The Effects of Remote Ischemic Preconditioning on the Inflammatory Cytokine Response to Free Flap Head and Neck Reconstruction: A Randomized Controlled Trial. | Microsurgery | 2026 | https://conductscience.org/library/papers/42536026 | PubMed |
| 42460029 | Co-formulation of IL-12 mRNA and doxorubicin in polymeric nanoparticles for simultaneous delivery in murine melanoma. | RSC Pharm | 2026 | https://conductscience.org/library/papers/42460029 | PubMed |
| 42450298 | Cartilage Oligomeric Matrix Protein (COMP) Correlates with Disease Progression, Selected Immune Checkpoint Molecules and SIGLEC9 in Colorectal Cancer. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42450298 | PubMed |
| 42386999 | Systemic health impact of cancer-associated extracellular vesicles and particles. | Nat Rev Cancer | 2026 | https://conductscience.org/library/papers/42386999 | PubMed |
| 42360103 | Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies. | J Enzyme Inhib Med Chem | 2026 | https://conductscience.org/library/papers/42360103 | PubMed |
| 42334072 | Immune Markers and Risk of Pancreatic Cancer in the European EPIC Cohort. | Int J Cancer | 2026 | https://conductscience.org/library/papers/42334072 | PubMed |
| 42318057 | Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42318057 | PubMed |
| 42302794 | TIGIT-targeted IL-12 fusion protein engages NK and CD8+ T cells for potent tumor immunotherapy. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42302794 | PubMed |
| 42292488 | Preliminary evaluation of a DDA cationic liposome-based pulmonary mucosal immunization platform carrying a SARS-CoV-2 spike-derived branched peptide. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292488 | PubMed |
Genes36
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33178203
GET https://conductscience.org/api/papers/v1/33178203/references?page=2